Related Experiment Video

Updated: Jul 13, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

MLC1 Overexpression Inhibits Tumor Progression through PI3K/AKT Signal Pathway in Prostate Cancer

Zonglin Wu1,2, Jinliang Ni3,4, Houliang Zhang3

  • 1Department of Urology, Putuo People's Hospital, School of Medicine, Tongji University, Shanghai, 200060, China.

Advanced Biology
|October 11, 2023
PubMed

Insights

MLC1 shows anti-tumor effects in prostate cancer (PC) by inhibiting the PI3K/AKT pathway. Lower MLC1 levels correlate with worse PC outcomes, suggesting its therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Prostate cancer (PC) is a significant male malignancy with high mortality.
  • MLC1 is implicated in tumor progression, but its specific role in PC is unknown.

Purpose of the Study:

  • To validate the anti-tumor effects of MLC1 in prostate cancer.
  • To elucidate the underlying molecular mechanisms of MLC1's action in PC.

Main Methods:

  • Analysis of MLC1 expression in PC using TCGA and GTEx databases.
  • In vitro experiments assessing proliferation, invasion, and migration upon MLC1 modulation.
  • In vivo studies evaluating tumor growth inhibition.
  • Investigation of the PI3K/AKT signaling pathway.

Main Results:

  • MLC1 expression is significantly decreased in PC tissues compared to normal tissues.
  • Reduced MLC1 correlates with increased metastasis and decreased patient survival.
  • Upregulating MLC1 inhibits PC cell proliferation, invasion, and migration via PI3K/AKT pathway deactivation.
  • Downregulating MLC1 promotes PC progression, reversed by Gefitinib.
  • MLC1 reduces tumor volume in vivo.

Conclusions:

  • MLC1 exhibits significant anti-tumor properties in prostate cancer.
  • MLC1 functions by inhibiting the PI3K/AKT signaling pathway.
  • MLC1 represents a potential therapeutic target for prostate cancer treatment.
Keywords:
PI3K/AKTin situ modelsmodulator of volume-regulated anion channel current 1 (MLC1)prostate cancer

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.1K